Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Recruiting now · Phase 3

Conditions studied: Non-Arteritic Anterior Ischemic Optic Neuropathy

In brief

This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).

Key facts

Study ID
NCT07453888
Run by
Dompé Farmaceutici S.p.A
People needed
272
Starts
2026-07-01
Expected to finish
2027-09-01
Last updated by the study team
2026-07-15

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.